<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043991</url>
  </required_header>
  <id_info>
    <org_study_id>8042</org_study_id>
    <nct_id>NCT01043991</nct_id>
  </id_info>
  <brief_title>Intracoronary Injection of Epo After Myocardial Infarct &quot;Intra-CO-EpoMI&quot;</brief_title>
  <official_title>Intracoronary Injection of Epo During Reperfusion in Patients Hospitalized for First Acute Myocardial Infarct STEMI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary endpoint: Is intracoronary injection of a single dose of darbepoetin alpha, during&#xD;
      reperfusion in patients hospitalized for ST segment elevation myocardial infarction (STEMI),&#xD;
      able to reduce infarct size ?&#xD;
&#xD;
      In in vivo studies, many experiments evidenced infarct size reduction, due to anti-apoptotic&#xD;
      compounds, when given during reperfusion, after cardiac ischemia. In humans,&#xD;
      post-conditioning offers such a protection, as the investigators have previously showed&#xD;
      (Staat P et al. Post-conditioning the human heart. Circulation. 2005 112(14):2143-8).&#xD;
&#xD;
      Infarct size reduction could lead to a reduced rate of complications (heart failure, rhythmic&#xD;
      complications) and finally, morbidity and even mortality. This protection depends on&#xD;
      anti-apoptotic properties (Zhao ZQ et al. Inhibition of myocardial injury by ischemic&#xD;
      postconditioning during reperfusion: comparison with ischemic preconditioning. Am J&#xD;
      Physiology Heart Circ Physiology 2003 Aug; 285(2):H579-88). Many drugs have been proposed to&#xD;
      be able to mimic this phenomenon. Among them, many are efficient but toxic in vivo or&#xD;
      difficult to manage (insulin, morphin). One of the most promising agent could then be&#xD;
      erythropoietin (EPO) (Opie LH et al. Postconditioning for protection of the infarcting heart.&#xD;
      Lancet. 2006; 367(9509):456-8). In order to target ischemia-reperfusion injuries, EPO impact&#xD;
      is better and better demonstrated (e.g.: Mudalagiri NR. Erythropoietin protects the human&#xD;
      myocardium against hypoxia and reoxygenation injury via phosphatidylinositol-3 kinase and&#xD;
      ERK1-2 activation. Br J Pharmacol. 2007 Oct 22). The purpose of the study is to test this&#xD;
      hypothesis in humans, on the onset of the reperfusion, after myocardial ischemia (acute&#xD;
      myocardial infarct). EPO could contribute to protect myocardium against ischemia-reperfusion&#xD;
      injury. This impact could rely on anti-apoptotic properties.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Centers.:&#xD;
&#xD;
      5 centers located in France:&#xD;
&#xD;
        -  Montpellier&#xD;
&#xD;
        -  Clermont-Ferrand&#xD;
&#xD;
        -  Lyon&#xD;
&#xD;
        -  Marseille&#xD;
&#xD;
        -  Nîmes&#xD;
&#xD;
      Study design: Open-label, placebo-controlled, single-blinded. Patient in treatment group will&#xD;
      receive intracoronary single bolus of EPO (150 µg), as soon as significant reperfusion is&#xD;
      obtained (as measured by TIMI flow 2 or 3). In control group, placebo will be used. Placebo&#xD;
      must be presented exactly the same as the drug.&#xD;
&#xD;
      Length of Treatment: One shot during reperfusion procedure.&#xD;
&#xD;
      Follow-up Period: 72nd hour post-admission for plasma kinetics of cardiac enzymes 5th to 7th&#xD;
      day after revascularization procedure for MRI measurements, and echocardiography3th month&#xD;
      post-MI MRI, echocardiography3th month: phone contact.&#xD;
&#xD;
      Sample Size: 27 patients in each arm, 54 patients total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic resonance imaging (MRI) determination of infarct size</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac enzymes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Acute Myocardial Infarct</condition>
  <arm_group>
    <arm_group_label>EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single bolus of EPO, 150 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <arm_group_label>EPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ACS with persistent ST elevation&#xD;
&#xD;
          -  First episode&#xD;
&#xD;
          -  Symptoms onset &lt; 12 hours&#xD;
&#xD;
          -  Eligible for angioplasty&#xD;
&#xD;
          -  Culprit coronary artery occluded (TIMI flow 0-1) at admission, and then adequately&#xD;
             reperfused (TIMI flow 2-3) prior to EPO injection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Cardiac arrest&#xD;
&#xD;
          -  Currently receiving EPO&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe PIOT, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>AMI,</keyword>
  <keyword>acute myocardial infarct</keyword>
  <keyword>Epo</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>ischemia-reperfusion</keyword>
  <keyword>apoptosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

